Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HemCon Medical Technologies

Request full access

HemCon Medical Technologies, Inc was built on a simple premise – to save lives

Portland, United StatesFounded 2001Biotech & Life Sciences

About HemCon Medical Technologies

Tricol Biomedical, formerly known as HemCon Medical Technologies, operates as a specialized medical device company focused on hemostatic and wound care management. The company was originally founded in 2001, with HemCon's co-founders including Dr. William "Bill" Wiesmann and Kenton Gregory. Dr. Wiesmann, a former U.S. Army medical researcher, leveraged his extensive experience in combat casualty care to spearhead the development of the company's core technology. His work was driven by the long-standing military need for a solution to control severe bleeding on the battlefield.

The company's history is rooted in a partnership with the U.S. Army, which began in 2001 to design a life-saving hemostatic dressing. This collaboration led to the creation of the HemCon bandage, which was released in 2003 and became the first advanced dressing of its kind used for rapid hemorrhage control in combat situations. The technology was recognized as one of the U.S. Army's "Top 10 Greatest Inventions" for its impact. In April 2016, the assets of HemCon Medical Technologies, including the brand name and product line, were acquired by Tricol International Group Ltd., and the company began operating as Tricol Biomedical, Inc. This acquisition was intended to merge Tricol's expertise in chitosan materials with HemCon's established presence in the wound care market, aiming for growth in surgical and chronic wound care sectors.

Tricol Biomedical develops, manufactures, and markets its products, which serve medical professionals in hospitals, military organizations, first responders, and consumers. The business model involves direct sales and partnerships with distributors, such as a significant 2021 agreement with Medline Industries, to broaden the reach of its product families across North America. The company's core product offering is based on its proprietary Chito+ technology, which utilizes chitosan, a naturally occurring polysaccharide derived from shrimp shells. The polycationic (positive) charge of the chitosan facilitates a strong bond with negatively charged tissues and blood cells, which helps to quickly seal wounds and control bleeding independently of the body's natural clotting process. The material also serves as an antibacterial barrier. The product portfolio is segmented into three main categories: Trauma Management for battlefield and pre-hospital settings; Procedural Care for controlling bleeding in clinical and surgical environments; and Consumer Self-Care for home use. Products are marketed under brand names including HemCon®, OneStop™, and m.doc®.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2001
Headquarters
Portland, United States
Employees
14
Open positions
None listed
Dealroom signal
42.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Mar 2007 $12M $48M Camden Partners · Torch Hill Investment Partners —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

HemCon Medical Technologies website traffic

Latest recorded traffic for HemCon Medical Technologies is 1.4K monthly website visits, up 16.7% over the last three months. HemCon Medical Technologies's team grew 7.7% over the past year.

Latest monthly visits1.4K 3-month web change+16.7% 1-year team growth+7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

HemCon Medical Technologies in the Portland ecosystem

Live from Dealroom

The HemCon Medical Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Camden Partners
  • Torch Hill Investment Partners

Other known investors1 additional known investor

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HemCon Medical Technologies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HemCon Medical Technologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.